XXII

+ Watchlist + Portfolio

22nd Century Group, Inc

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.98
52-Week Range: $3.61 – $648.00
Market Cap: $1.98M
P/E (TTM): —
EPS (TTM): -650.73
Dividend Yield: —

Advanced Metrics

Price/Book: 0.13
PEG Ratio: —
Return on Equity: -105.72%
Return on Assets: -30.95%
Gross Margin: -54.60%
Operating Margin: -247.82%
Profit Margin: -76.01%
Current Ratio: 2.61
Debt/Equity: 0.09
Total Debt: $1.75M
Free Cash Flow: $-14.74M
Revenue Growth: -40.40%
Earnings Growth: —
Enterprise Value: $-1.50M

XXII Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$40.50M	$16.20M	$11.88M	$7.05M
Cost of Revenue	$38.65M	$24.89M	$14.28M	$10.19M
Gross Profit	$1.85M	-$8.70M	-$2.40M	-$3.14M
Research & Development	$3.58M	$2.64M	$1.13M	$688.00K
Selling, General & Admin	$32.23M	$31.06M	$10.29M	$7.59M
Operating Expenses	$35.81M	$33.71M	$11.42M	$8.28M
Operating Income	-$33.96M	-$42.40M	-$13.82M	-$11.42M
EBITDA	-$32.89M	-$40.41M	-$12.11M	-$10.53M
Pretax Income	-$36.53M	-$54.64M	-$15.46M	-$13.14M
Income Tax	$21.00K	$47.00K	$30.00K	-$28.00K
Net Income	-$59.80M	-$140.78M	-$15.16M	-$5.05M
Diluted EPS	-3147421.05	-75383500.00	-242542.86	-1057.40
Diluted Shares	19	2	105	9203

XXII Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$2.21M	$2.06M	$4.42M	$7.15M
Receivables	$1.36M	$3.67M	$2.20M	$3.59M
Inventory	$7.27M	$4.35M	$2.02M	$4.33M
Current Assets	$44.60M	$16.28M	$11.52M	$17.63M
Total Assets	$114.65M	$27.50M	$21.67M	$27.02M
Current Liabilities	$13.02M	$25.03M	$9.96M	$7.27M
Long-Term Debt	$3.00M	$8.06M	$5.17M	$504.00K
Total Debt	$1.65M	$16.38M	$8.62M	$1.48M
Total Liabilities	$18.68M	$35.91M	$17.66M	$11.27M
Retained Earnings	-$237.81M	-$378.71M	-$393.87M	-$398.93M
Shareholders' Equity	$95.97M	-$8.41M	$4.01M	$15.76M
Working Capital	$31.59M	-$8.76M	$1.56M	$10.36M
Net Debt	$889.00K	$12.39M	$2.50M	—

XXII Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$51.71M	-$54.99M	-$14.35M	-$7.72M
Capital Expenditure	-$4.43M	-$5.62M	-$161.00K	-$875.00K
Free Cash Flow	-$56.14M	-$60.60M	-$14.51M	-$8.60M
Depreciation & Amortisation	$3.59M	$4.86M	$1.26M	$1.16M
Stock-Based Compensation	$5.49M	$2.68M	$380.00K	$421.00K
Investing Cash Flow	$22.58M	$16.82M	-$139.00K	-$505.00K
Financing Cash Flow	$30.82M	$37.21M	$16.85M	$10.96M
Share Repurchases	$0.00	-$178.00K	$0.00	—
Net Change in Cash	$1.68M	-$962.00K	$2.36M	$2.73M

XXII Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$2.27M	$2.23M	$1.50M	$1.05M	$1.29M
Cost of Revenue	$2.88M	$2.86M	$2.56M	$1.88M	$1.93M
Gross Profit	-$609.00K	-$635.00K	-$1.06M	-$834.00K	-$636.00K
Research & Development	$162.00K	$227.00K	$193.00K	$105.00K	$285.00K
Selling, General & Admin	$1.80M	$2.12M	$1.85M	$1.82M	$2.12M
Operating Expenses	$1.96M	$2.35M	$2.15M	$1.82M	$2.40M
Operating Income	-$2.57M	-$2.98M	-$3.21M	-$2.65M	-$3.04M
EBITDA	-$2.42M	-$2.67M	-$2.92M	-$2.51M	-$2.76M
Pretax Income	-$3.27M	-$3.33M	-$3.76M	-$2.78M	-$3.02M
Income Tax	$0.00	-$34.00K	$0.00	$6.00K	$0.00
Net Income	-$4.33M	-$3.41M	$5.49M	-$2.81M	-$3.26M
Diluted EPS	-10929.29	-2229.71	-84.00	—	-361.60
Diluted Shares	396	1528	39628	—	29767

XXII Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$1.13M	$3.08M	$4.85M	$7.15M	$9.54M
Receivables	$4.32M	$3.54M	$2.99M	$3.59M	$4.78M
Inventory	$2.56M	$2.50M	$2.91M	$4.33M	$4.35M
Current Assets	$11.10M	$11.87M	$22.92M	$17.63M	$21.07M
Total Assets	$21.46M	$22.38M	$32.37M	$27.02M	$30.31M
Current Liabilities	$16.40M	$15.39M	$10.54M	$7.27M	$7.91M
Long-Term Debt	—	—	—	$504.00K	$475.00K
Total Debt	$5.56M	$5.43M	$1.18M	$1.48M	$1.32M
Total Liabilities	$17.83M	$16.75M	$11.26M	$11.27M	$9.09M
Retained Earnings	-$398.20M	-$401.61M	-$396.12M	-$398.93M	-$402.19M
Shareholders' Equity	$3.63M	$5.63M	$21.10M	$15.76M	$21.22M
Working Capital	-$5.30M	-$3.52M	$12.38M	$10.36M	$13.16M
Net Debt	$2.80M	$773.00K	—	—	—

XXII Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$2.98M	-$3.48M	-$4.02M	$2.75M	-$3.10M
Capital Expenditure	-$59.00K	-$39.00K	-$22.00K	-$755.00K	-$47.00K
Free Cash Flow	-$3.04M	-$3.52M	-$4.04M	$1.99M	-$3.15M
Depreciation & Amortisation	$291.00K	$304.00K	$305.00K	$257.00K	$246.00K
Stock-Based Compensation	$26.00K	$107.00K	$92.00K	$196.00K	$238.00K
Investing Cash Flow	-$59.00K	$731.00K	-$522.00K	-$655.00K	-$47.00K
Financing Cash Flow	-$254.00K	$4.70M	$6.30M	$209.00K	$5.55M
Share Repurchases	$0.00	—	—	—	-$9.65M
Net Change in Cash	-$3.29M	$1.95M	$1.76M	$2.30M	$2.40M

Market Snapshot

About

22nd Century Group is a plant biotechnology company focused on tobacco harm reduction and hemp/cannabis research. The company uses genetic engineering and plant breeding to develop tobacco plants with reduced nicotine content and hemp plants with specific cannabinoid profiles. 22nd Century aims to address public health concerns while creating novel plant-based products.